HANGZHOU, China, March 26 /PRNewswire-FirstCall/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC) announced today that it has reached agreement with Beijing Keyuan Xinhai Pharmaceutical Company to launch newly approved pharmaceutical products made by leading international pharmaceutical companies. According to the agreement, China Biopharma will distribute pharmaceutical products made by international companies including human vaccines in China using its sales network and distribution logistics.
In the last few months, the company has made effort to extend its market scope and establish new partnership in addition to the original JV partner, Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd. Due to certain local tax regulations the Company's sales of the products of its original JV partner could not be fully recognized. In order to effectively conduct its business operation and change from its passive marketing approach in China, the Company has shifted its market strategy to working more closely with new pharmaceutical products from global leading pharmaceutical companies in addition to local products. "We are very excited about the agreement we have reached with Beijing Keyuan Xinhai Pharmaceutical Company," said Mr. Qiumeng Wang, the Company's COO. "It will significantly improve our current operation situation." Beijing Keyuan Xinhai Pharmaceutical Company is one of the largest imported pharmaceutical product providers in China.
About China Biopharma, Inc.
China Biopharma Inc. is a biopharmaceutical company based in China. Through its operating subsidiaries, the company develops and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include human vaccines and other pharmaceutical drugs. Leveraging its local presents and the relationship with local Chinese bio-pharmaceutical companies and international biopharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as new world markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.net.
Safe Harbor Statement
Some of the statements here discuss future events and developments,
including the Company's future business strategy and its ability to
generate revenue, income and cash flow, and should be considered
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These "forward-looking" statements can
generally be identified by words such as "expect," "anticipate," "believe,"
"estimate," "intend," "plan," and similar expressions. These statements
involve a high degree of risk and uncertainty that exists in the Company's
operations and business environment and are subject to change based on
various factors that could cause actual Company results, performance,
plans, goals and objectives to differ materially from those contemplated or
implied in these forward-looking statements. Actual results may be
different from anticipated results for a number of reasons, including the
Company's new and uncertain business model, uncertainty regarding
acceptance of the Company's products and services and the Company's limited
China Biopharma, Inc.
Tel: +1 (609) 651-8588
|SOURCE China Biopharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved